Abstract WP119: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
The Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, is a prospective, randomized, double-blind, multicenter trial with the primary null hypothesis that, in patients with TIA or minor ischemic stroke treated with aspirin 50-325 mg/day, there is no difference in survival free of ischemic stroke, myocardial infarction, and ischemic vascular death at 90 days in those treated with clopidogrel (600 mg loading dose then 75 mg/day) compared to placebo when therapy is initiated within 12 hours of the time last known free of new ischemic symptoms.
Subjects are 18 years of age or older with high-risk TIA (defined as an ABCD2 score > 4) or minor ischemic stroke (with an NIHSS < 3); each subject is followed for 90 days from randomization. A total of 4,150 patients will be recruited and the trial will be completed in 7 years. The first subject was enrolled on May 28, 2010.
Planned Number of Centers: 210; Present Number: 145 (06 AUG 2012)
Planned Number of Subjects: 4,150; Present Number: 1,008 (06 AUG 2012)
Sponsor: University of California, San Francisco (UCSF); National Institute of Neurological Disorders and Stroke (NINDS)
Collaborators: Neurological Emergencies Treatment Trials Network (NETT); Statistics and Data Management Center (SDMC) at Medical University of South Carolina (MUSC); POINT Clinical Research Collaboration (POINT CRC) at EMMES Corporation
Dates of Study: October 2009 - September 2016
- © 2012 by American Heart Association, Inc.